Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00139971
Recruitment Status : Unknown
Verified August 2005 by West Japan Thoracic Oncology Group. Recruitment status was: Recruiting
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
completely resected non small cell lung cancer
no prior anti cancer treatment for thoracic malignancy exept for this operation
pathological stage IB, II, and stage IIIA with only one station of n2 disease
adequate organ function for chemotherapy
written informed consent
small cell lung cancer or low grade malignancy of lung cancer
apparent interstitial pneumonitis at chest rentogenogram